-
Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment
•
US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System has received CE marking, a significant step in expanding its market reach for this minimally invasive alternative to open-heart surgery. The Harmony TPV System is designed for patients with congenital heart disease, specifically those with…
-
Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology
•
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia, a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). Combining ExpertiseThe…
-
Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Sarclisa (isatuximab) in combination with pomalidomide plus dexamethasone. This approval is for the treatment of adult patients with multiple myeloma who have previously received at least first-line…
-
Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development
•
Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license agreement with Chugai Pharmaceutical Co., Ltd. The partnership will utilize Araris’ proprietary linker-conjugation platform, AraLinQ, to generate novel antibody drug conjugates (ADCs) using antibodies against undisclosed targets provided by the Japanese firm. Deal Terms and…
-
Mirror Biologics and Merck KGaA Collaborate on Phase II Trial for Colorectal Cancer Immunotherapy
•
US-based Mirror Biologics, Inc., an off-the-shelf immunotherapy developer, has announced a clinical trial collaboration and supply agreement with German major Merck KGaA (ETR: MRK). The collaboration aims to jointly conduct a Phase II clinical study assessing the efficacy and safety of Mirror’s immunotherapy AlloStim combined with Merck’s Bavencio (avelumab), an…
-
Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast Track designation from the US FDA for its posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) targeting Alzheimer’s disease (AD). This designation is a significant milestone in the development of posdinemab, which is designed to slow…
-
Boston Scientific Set to Acquire Bolt Medical for Up to USD 900 Million
•
US major Boston Scientific Corporation (NYSE: BSX) is set to acquire Bolt Medical, Inc., a company founded in 2019 with Boston Scientific’s backing, in which it currently holds a 26% stake. The transaction is structured to include an upfront payment of USD 43 million for the remaining 74% ownership that…
-
China’s Central Committee and State Council Outline Reforms for Elderly Care Services
•
The Communist Party of China (CPC) Central Committee and State Council have released the Opinions on Deepening the Reform and Development of Elderly Care Services. The aim is to accelerate the construction of an elderly care service system suitable for China’s national conditions, ensuring that the elderly have a sense…
-
Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery
•
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary Ailux Biologics has struck a partnership with UCB (EBR: UCB), granting the Belgian biopharma commercial rights to utilize Ailux’s XtalFold AI platform for the discovery and engineering design of macromolecular drugs. No financial details were…
-
Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418
•
On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced that they have entered into an exclusive license agreement. Under the agreement, Avenzo will obtain exclusive rights to develop, manufacture, and commercialize DB-1418/AVZO-1418 globally, excluding Greater China. DB-1418/AVZO-1418 is an EGFR/HER3 bispecific antibody-drug conjugate (ADC)…
-
MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26
•
US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human papillomavirus (HPV) quadrivalent vaccine, Gardasil, for use in males aged 9 to 26. This approval expands the vaccine’s application to include prevention…
-
Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication
•
Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA) for its Nubeqa (darolutamide) to the National Medical Products Administration (NMPA) in China. The German pharmaceutical giant is seeking approval for its androgen receptor inhibitor (ARi) combined with androgen deprivation therapy (ADT) for the treatment…
-
GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced that it has received clearance from China’s National Medical Products Administration (NMPA) to launch its imaging guided therapy angiography system, Allia IGS Pulse, in China. This follows the US FDA’s approval in October 2023. System…
-
Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418
•
US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an antibody conjugate drug (ADC) developer operating out of the United States and China, for AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC. Drug Profile and DevelopmentAVZO-1418/DB-1418 is an EGFR/HER3 dual-targeting ADC based on a topoisomerase-1 inhibitor.…
-
Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors
•
US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance the potential best-in-class chimeric antigen receptor (CAR)-T therapy, IB-T101, for the treatment of solid tumors. This collaboration combines the expertise of two cell therapy specialists to enhance the development and commercialization of innovative cancer treatments.…
-
Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies
•
China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have agreed to collaborate on the overseas business development of Kelun’s high-end generic drugs and innovative therapies. The partnership aims to leverage the strengths of both companies to expand their global footprint. Agreement DetailsUnder the terms…
-
PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project
•
Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution giant Baheal Pharmaceutical Group for its integrin-targeted small molecule inhibitor project. The deal, valued at RMB 70 million (USD 9.5 million), grants Baheal exclusive global rights for patent, clinical development and regulatory filing, manufacturing, and…
-
Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project
•
Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly launched a project focused on developing a generative artificial intelligence (AI)-based rare disease large language model and assisted screening and diagnosis digital solution. This collaboration aims to enhance the early screening and diagnosis of rare…
-
LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors
•
LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds of millions” of renminbi in a Series E financing round. The funding was led by Wuxi Venture Capital and BHIDG, both state-owned enterprises. This investment will support the company’s ongoing expansion and innovation in the…
-
Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China
•
China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co., Ltd., becoming the exclusive commercialization partner for CPL-01 (ropivacaine sustained-release injection) in China. Under the agreement, Grand Life Sciences will pay Cali Biosciences an undisclosed amount of upfront and milestone payments, while Cali Biosciences will…
